Propensity Score Analysis: Hyper-CVAD (HCVAD) + Ponatinib vs. HCVAD + Dasatinib in Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) ALL (ALL)

The phase II of HCVAD + ponatinib achieved excellent outcome compared to that of HCVAD + dasatinib.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Koji Sasaki, Elias Jabbour, Farhad Ravandi, Nicholas Short, Rita Khouri, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Tapan Kadia, Marina Konopleva, Nitin Jain, Ghayas Issa, Vicki Jeanis, Gal Moore, Rebecca Garris, Naveen Pemmaraju, Jorge Cortes, Source Type: research